Tutorials
Keros Therapeutics Inc logo

Keros Therapeutics Inc

$ 39.43 +1.68 (+4.45%) 08:09 PM EST
P/E:
At Loss
P/B:
4.56
Market Cap:
$ 1.02B
Enterprise V:
$ 800.65M
Volume:
120.97K
Avg Vol (2M):
249.08K
Volume:
120.97K
Market Cap $:
1.02B
PE Ratio:
At Loss
Avg Vol (2-Month):
249.08K
Enterprise Value $:
800.65M
PB Ratio:
4.56
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download Tutorials

Business Description

Keros Therapeutics Inc
NAICS : 325412 SIC : 2833
99 Hayden Avenue, Suite 120, Building E, Lexington, MA, USA, 02421
Description
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
Name Current Vs Industry Vs History
Cash-To-Debt 321.82
Equity-to-Asset 0.93
Debt-to-EBITDA -0.01
Piotroski F-Score 4/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 38.42
Distress
Grey
Safe
Beneish M-Score 180.5
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year Revenue Growth Rate -8.6
3-Year EBITDA Growth Rate -140.8
3-Year EPS without NRI Growth Rate -156.1

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 71.16
9-Day RSI 69.02
14-Day RSI 65.51
6-1 Month Momentum % -43.79
12-1 Month Momentum % -16.38

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 14.39
Quick Ratio 14.39
Cash Ratio 13.95
Days Sales Outstanding 165.16

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -39.2

Financials (Next Earnings Date:2022-11-04 Est.)

KROS's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:KROS

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 20
EPS (TTM) ($) -3.31
Beta 0
Volatility % 67.39
14-Day RSI 65.51
14-Day ATR ($) 2.847384
20-Day SMA ($) 33.003
12-1 Month Momentum % -16.38
52-Week Range ($) 24.38 - 68.29
Shares Outstanding (Mil) 25.76

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 4
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Keros Therapeutics Inc Filings

Document Form Filing Date
No Filing Data

Headlines

See More